Frequent oral ulceration during early disease may predict a severe disease course in males with Behçet's syndrome

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Hamuryudan, Vedat ^a   Hatemi, Gulen ^a   Sut, Necdet ^b   Ugurlu, Serdal ^a   Yurdakul, Sebahattin ^a   Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b TRAKYA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Beh et's disease; Major organ involvement; Oral ulcers; Outcome; Prognosis

Indexed keywords

PLACEBO; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED DISEASE; ERYTHEMA NODOSUM; FOLLICULAR LESION; GENITAL ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUTH ULCER; ONSET AGE; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ADOLESCENT; AGE; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TIME; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGE FACTORS; BEHCET SYNDROME; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; ORAL ULCER; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; THALIDOMIDE; TIME FACTORS; TURKEY; YOUNG ADULT;

EID: 84873257929     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. YURDAKUL S, YAZICI H. Behçet's syndrome. Best Pract Res Clin Rheumatol 2008; 22: 793-809.
2. KURAL-SEYAHI E, FRESKO I, SEYAHI N et al.: The long-term mortality and morbidity of Behçet's syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 60-76.
3. HAMURYUDAN V, OZYAZGAN Y, HIZLI N et al.: Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40: 769-74.
4. YAZICI H, TÜZÜN Y, PAZARLI H et al.: Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984; 43: 783-9.
5. IDEGUCHI H, SUDA A, TAKENO M, UEDA A, OHNO S, ISHIGATSUBO Y. Behçet disease. Evolution of clinical manifestations. Medicine (Baltimore) 2011; 90: 125-32.
6. HAMURYUDAN V, HATEMI G, TASCILAR K et al.: Prognosis of Behçet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 2010; 49: 173-7.
7. HAMURYUDAN V, MAT C, SAIP S et al.: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443-50.
8. INTERNATIONAL STUDY GROUP FOR BEHÇET DISEASE: Criteria for diagnosis of Behçet disease. Lancet 1990; 335: 1078-80.
9. ALPSOY E, DONMEZ L, ONDER M et al.: Clinical features and natural course of Behçet's disease in 661 patients: a multicenter study. Br J Dermatol 2007; 157: 901-6.
10. SACLI FS, SEYAHI E, UGURLU S, OZYAZGAN Y, Mat C, YAZICI H. Some manifestations disappear earlier than others in Behçet's syndrome. Arthritis Rheum 2011; 63 (Suppl.): S934.
11. HATEMI G, YAZICI H. Behçet's syndrome and micro-organisms. Best Pract Res Clin Rheumatol 2011; 25: 389-406.
12. MUMCU G, Sur H, INANC N et al.: A composite index for determining the impact of oral ulcer activity in Behçet's disease and recurrent aphthous stomatitis. J Oral Pathol Med 2009; 38: 785-91.
13. KRAUSE I, ROSEN Y, KAPLAN I et al.: Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 1999; 28: 193-6.
14. OH SH, HAN EC, LEE JH, BANG D. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet's disease. Clin Exp Dermatol 2009; 34: e208-12.